Kodiak Sciences is a biopharmaceutical company developing therapies for retinal diseases using its proprietary Antibody Biopolymer Conjugate platform technology. The company's lead program, tarcocimab (Zenkuda), is a long-acting anti-VEGF treatment designed to provide extended durability between doses compared to existing agents, with additional candidates in development targeting broader disease mechanisms combining anti-inflammatory and anti-VEGF properties. Kodiak plans to generate revenue through direct commercialization of its product candidates to ophthalmologists and retina specialists in major retinal disease markets including diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, with a proprietary patent portfolio protecting its core technology and manufacturing processes.